China Metastatic Liver Cancer Clinical Registry Cohort Database

NCT07602504 — Recruiting, 2000 participants, Anhui Provincial Hospital

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT07602504
Status	Recruiting
Study type	Observational
Enrollment	2000 (Estimated)
Sponsor	Anhui Provincial Hospital (Other gov)
Conditions	Liver Metastases, Metastases to Liver, Liver Cancer, Neoplasms, Liver Diseases, Colorectal Cancer Metastatic
Interventions	Standard of Care for Metastatic Liver Cancer (Procedure)
Dates	start 2026-06-01 (estimated), primary completion 2031-05-31 (estimated), completion 2036-05-31 (estimated), first posted 2026-05-22, last updated 2026-05-22
Locations	3 sites in China

-Summary

This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.

Expand all sections · Collapse all

+Arms and interventions

Standard of Care for Metastatic Liver Cancer (Procedure): In this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions.

+Outcome measures

Primary outcomes

Overall Survival [Up to 10 years]: The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.

Secondary outcomes

Progression-Free Survival [Up to 10 years]: Description: The time interval from the date of enrollment (or initial treatment) to the date of the first documented disease progression (local recurrence or distant metastasis) or death from any cause, whichever occurs first.
Treatment-Related Adverse Events [Within 90 days post-treatment]: The incidence and severity of postoperative complications or treatment-related adverse events, graded according to the Clavien-Dindo classification (for surgical complications) or CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.

+Eligibility

Sex: All, ages: 18 Years to 80 Years

Inclusion Criteria:

1. Patients with histologically or radiologically confirmed metastatic liver cancer.
2. Age ≥ 18 years.
3. Patients who have voluntarily signed the informed consent form.
4. Patients with complete baseline clinical data.

Exclusion Criteria:

1. Patients with primary liver cancer (e.g., hepatocellular carcinoma).
2. Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
3. Patients who have previously participated in other interventional clinical trials.
4. Patients with severe cognitive disorders or communication barriers that prevent informed consent.
5. Patients with incomplete or missing key clinical data.

+Locations (3)

Facility	City	Country	Status
The First Affiliated Hospital of Bengbu Medical University	Bengbu, Anhui	China	Not yet recruiting
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)	Hefei, Anhui	China	Recruiting
The Affiliated Hospital of Qingdao University	Qingdao, Shandong	China	Recruiting